Founded in 1991 by Alfred E. Mann, a medtech visionary who played a large part in the wider adoption of insulin pumps as the founder of MiniMed, the company develops Afrezza — a fast-acting insulin formulation delivered through an inhaler device.

Initially approved in 2014 as a rapid-acting inhaled insulin to improve glycemic management in adults with diabetes, the offering serves type 2 diabetes and people with type 1 diabetes who use it alongside a long-acting insulin. With recent data further supporting Afrezza, not only against the current standards of care but in the pediatric population, the company could take it even further.

Speaking with Drug Delivery Business News at the American Diabetes Association’s 85th Scientific Sessions in Chicago, MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, explained the benefits of the inhaled insulin technology.